These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
238 related articles for article (PubMed ID: 2216629)
21. American Academy of Pediatrics Committee on Infectious Diseases: Haemophilus influenzae type b conjugate vaccines: recommendations for immunization with recently and previously licensed vaccines. Pediatrics; 1993 Sep; 92(3):480-8. PubMed ID: 8361814 [No Abstract] [Full Text] [Related]
22. Reduction of oropharyngeal carriage of Haemophilus influenzae type b (Hib) in children immunized with an Hib conjugate vaccine. Takala AK; Eskola J; Leinonen M; Käyhty H; Nissinen A; Pekkanen E; Mäkelä PH J Infect Dis; 1991 Nov; 164(5):982-6. PubMed ID: 1940479 [TBL] [Abstract][Full Text] [Related]
23. Immune response of young children vaccinated with Haemophilus influenzae type b conjugate vaccines. Madore DV; Phipps DC; Eby R; Johnson CL; Smith DH Contrib Microbiol Immunol; 1989; 10():125-50. PubMed ID: 2684505 [No Abstract] [Full Text] [Related]
25. Passive immunization for infection with Haemophilus influenzae type b. Santosham M; Reid R; Letson GW; Wolff MC; Siber G Pediatrics; 1990 Apr; 85(4 Pt 2):662-6. PubMed ID: 2179857 [TBL] [Abstract][Full Text] [Related]
26. FDA approval of use of a new Haemophilus b conjugate vaccine and a combined diphtheria-tetanus-pertussis and Haemophilus b conjugate vaccine for infants and children. Centers for Disease Control and Prevention (CDC) MMWR Morb Mortal Wkly Rep; 1993 Apr; 42(15):296-8. PubMed ID: 8479415 [No Abstract] [Full Text] [Related]
27. Further immunologic evaluation of children who develop haemophilus disease despite previous vaccination with type b polysaccharide vaccine. Granoff DM; Sheetz KE; Nahm MH; Madassery JV; Shackelford PG Monogr Allergy; 1988; 23():256-68. PubMed ID: 3260336 [No Abstract] [Full Text] [Related]
28. Prevention of Haemophilus influenzae type b disease: vaccines and passive prophylaxis. Wenger JD; Ward JI; Broome CV Curr Clin Top Infect Dis; 1989; 10():306-39. PubMed ID: 2679698 [No Abstract] [Full Text] [Related]
29. Evaluating the Haemophilus influenzae type b conjugate vaccine PRP-D. Robbins JB; Schneerson R N Engl J Med; 1990 Nov; 323(20):1415-6. PubMed ID: 2233910 [No Abstract] [Full Text] [Related]
30. Finnish efficacy trials with Haemophilus influenzae type b vaccines. Eskola J; Peltola H; Käyhty H; Takala AK; Mäkelä PH J Infect Dis; 1992 Jun; 165 Suppl 1():S137-8. PubMed ID: 1588148 [TBL] [Abstract][Full Text] [Related]
31. Safety and immunogenicity of two Haemophilus influenzae type b polysaccharide-tetanus toxoid conjugate vaccines (PRP-T) given with diphtheria-tetanus-pertussis vaccine to young Papua New Guinean children. Lehmann D; Kakazo M; Saleu G; Taime J; Javati A; Namuigi P; Alpers MP; Wegmüller B; Zellmeyer M; Fürer E; Que JU; Herzog C P N G Med J; 2001; 44(1-2):6-16. PubMed ID: 12418673 [TBL] [Abstract][Full Text] [Related]
32. Responses of children to booster immunization with their primary conjugate Haemophilus influenzae type B vaccine or with polyribosylribitol phosphate conjugated with diphtheria toxoid. Decker MD; Edwards KM; Bradley R; Palmer P J Pediatr; 1993 Mar; 122(3):410-3. PubMed ID: 8441096 [TBL] [Abstract][Full Text] [Related]
33. Serum antibodies in six-year-old children vaccinated in infancy with a Haemophilus influenzae type b-tetanus toxoid conjugate vaccine. Claesson BA; Trollfors B; Anderson PW; Johansson J; Taranger J; Schneerson R; Robbins JB Pediatr Infect Dis J; 1996 Feb; 15(2):170-2. PubMed ID: 8822293 [No Abstract] [Full Text] [Related]
34. Commentary: results of efficacy trials in Alaska and Finland of Haemophilus influenzae type b conjugate vaccine. Ward J Pediatrics; 1990 Apr; 85(4 Pt 2):667. PubMed ID: 2179858 [No Abstract] [Full Text] [Related]
35. Disappearance of epiglottitis during large-scale vaccination with Haemophilus influenzae type B conjugate vaccine among children in Finland. Takala AK; Peltola H; Eskola J Laryngoscope; 1994 Jun; 104(6 Pt 1):731-5. PubMed ID: 8196448 [TBL] [Abstract][Full Text] [Related]
36. Haemophilus b conjugate vaccines for prevention of Haemophilus influenzae type b disease among infants and children two months of age and older. Recommendations of the immunization practices advisory committee (ACIP). MMWR Recomm Rep; 1991 Jan; 40(RR-1):1-7. PubMed ID: 1899280 [TBL] [Abstract][Full Text] [Related]
37. Immunogenicity of Haemophilus influenzae oligosaccharide-protein and polysaccharide-protein conjugate vaccination of children at 4, 6, and 14 months of age. Käyhty H; Peltola H; Eskola J; Rönnberg PR; Kela E; Karanko V; Mäkelä PH Pediatrics; 1989 Dec; 84(6):995-9. PubMed ID: 2587155 [TBL] [Abstract][Full Text] [Related]
38. Immunogenicity of the Haemophilus influenzae type b capsular polysaccharide conjugate vaccine in children after systemic Haemophilus influenzae type b infections. Kaplan SL; Zahradnik JM; Mason EO; Dukes CM J Pediatr; 1988 Aug; 113(2):272-7. PubMed ID: 3260943 [TBL] [Abstract][Full Text] [Related]
39. Safety and immunologic response to Haemophilus influenzae type b oligosaccharide-CRM197 conjugate vaccine in 1- to 6-month-old infants. Madore DV; Johnson CL; Phipps DC; Popejoy LA; Eby R; Smith DH Pediatrics; 1990 Mar; 85(3):331-7. PubMed ID: 2304786 [TBL] [Abstract][Full Text] [Related]
40. Limited efficacy of a Haemophilus influenzae type b conjugate vaccine in Alaska Native infants. The Alaska H. influenzae Vaccine Study Group. Ward J; Brenneman G; Letson GW; Heyward WL N Engl J Med; 1990 Nov; 323(20):1393-401. PubMed ID: 2233906 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]